Whitehawk Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
6analysts covering
FY Revenue (est.)
$-1.1Mnext fiscal year
FY EPS (est.)
-$1.11next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 5 Nov 2026 |
| Q4 and Full-Year 2026 Financial Results | 11 Mar 2027 |
Monitoring Framework
Key Performance Indicators
HWK-007 Phase 1 Dose-Escalation Enrollment QuarterlyTarget: Initial Phase 1 data readout
HWK-016 Phase 1 Dose-Escalation Enrollment QuarterlyTarget: Initial Phase 1 data readout
HWK-206 IND Submission QuarterlyTarget: IND submission to FDA
Cash Runway (Years) Quarterly2.0Target: Extend operations into 2H 2028
Watch Items
- HWK-206 Phase 1 Trial InitiationTrigger: Q3 2026Action: Monitor clinical trial registry (NCT) for study activation and first patient dosed.
- Initial Phase 1 Data Readouts for HWK-007 and HWK-016Trigger: First Half of 2027 (1H 2027)Action: Evaluate safety, tolerability, and preliminary efficacy signals (ORR, DCR) to validate the CBCR platform.
- Cash Burn Rate and Capital SufficiencyTrigger: Quarterly cash burn exceeding $25 millionAction: Re-assess cash runway projections and monitor for potential dilutive financing or strategic partnerships.
Research as of 19 Jun 2026